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ABSTRACT
Cutaneous adverse drug reactions are very common in a hospital setting while treating patients. Drug-induced vasculitis is a very common form 
of vasculitis affecting all age groups, and many drugs have been implicated in causing vasculitis. Clopidogrel is an antiplatelet drug used in the 
management as well as prevention of coronary artery disease. It is known to cause various side effects ranging from bleeding, gastrointestinal 
disturbances, to skin rashes. Leukocytoclastic vasculitis is a form of hypersensitivity vasculitis and is very rarely seen with clopidogrel. Hence, we 
report a case of clopidogrel-induced leukocytoclastic vasculitis in an old male patient after coronary stenting. 
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INTRODUCTION
Drug-induced vasculitis is one of the most common forms of 
vasculitis causing inflammation of the blood vessels by use of various 
pharmacological agents. It usually resembles idiopathic vasculitis, but 
stopping of the offending agent along with histopathological analysis 
usually helps in identifying the condition. Various drugs associated with 
vasculitis include antibiotics, antipsychotic agents, anti-tumor necrosis 
factor alpha agents, and other agents such as lithium and allopurinol [1]. 
Hence, we report a case of clopidogrel induced leukocytoclastic 
vasculitis in a 65-year-old male patient post-percutaneous transluminal 
coronary angioplasty in a tertiary care hospital in Southern India.
CASE REPORT
Informed consent was taken from the patient. A 65-year-old male 
patient came with complaints of profuse sweating with giddiness on 
April 6, 2016. His vitals were stable with heart rate of 75 beats/minutes 
and blood pressure of 140/80 mmHg. Cardiovascular examination 
revealed normal S1 and S2, and respiratory system examination 
revealed respiratory breath sounds to be normal. Chest X-ray was 
normal with no cardiomegaly and normal pulmonary vasculature was 
seen. Electrocardiography revealed evolved inferior wall myocardial 
infarction. Echocardiography revealed no regional wall motion 
abnormality and normal left ventricle resting systolic function. Hence, 
the patient was treated with intravenous nitroglycerin, heparin, 
antiplatelet, diuretics, beta-blockers, and statins and was stabilized. 
Hence, diagnosis of ischemic heart disease with evolved inferior wall 
myocardial infarction and was referred to tertiary medical center on 
April 9, 2015. Coronary angiography revealed coronary artery disease 
with proximal left anterior descending artery 80% lesion, proximal 
right coronary artery total occlusion, and left circumflex artery to 
be normal. Then, after confirming the lesion, patient underwent 
percutaneous transluminal coronary angioplasty with stenting to left 
anterior descending artery and right coronary artery and was put on 
sustained release nitroglycerine 30 mg, aspirin 150 mg, clopidogrel 
300 mg loading dose followed by 75 mg, nicorandil 10 mg, amlodipine 
5 mg, rosuvastatin 40 mg, and pantoprazole 40 mg. Beta-blockers were 
not advised in view of complete heart blockade post-intervention. The 
patient was discharged on April 11, 2015. Two months later, the patient 
complained of burning sensation in legs with maculopapular rash along 
with palpable purpura on the right forearm (Fig. 1). A diagnosis of 
leukocytoclastic vasculitis was made. Clopidogrel was suspected as the 
cause after ruling out other conditions, and dose was reduced to 50 mg 
once daily. In 2 weeks, the lesions subsided and the patient condition 
improved.
DISCUSSION
Leukocytoclastic vasculitis, also called the hypersensitivity vasculitis, 
affects predominantly the small vessels with no gender predilection 
with an incidence of 30 million cases/year globally [2]. Most 
common affected organ is the skin with more predilections for lower 
extremities, but one-third of cases affect the trunk as well as the upper 
extremities. It usually presents as painful burning rash, palpable 
purpura, sometimes also presents as maculopapular rash, bullae, 
plaques and ulcer [2]. Various etiological factors known to cause 
this condition include infections, drugs, collagen vascular disorder, 
autoimmune conditions, foods, and malignancies. The differential 
diagnosis includes Henoch-Schonlein purpura, drug-related 
eosinophilia and systemic symptoms, amyloidosis, meningococcemia, 
immune thrombocytopenic purpura, and antiphospholipid antibody 
syndrome. Circulating immune complex is involved, but the 
pathogenesis is still unclear [2].
Clopidogrel is a thienopyridine derivative, used in the treatment as well 
as the prevention of coronary vascular disease. It acts by irreversibly 
inhibiting the P2Y12 receptors on the platelet surface and thereby 
inhibits the ADP and fibrinogen induced platelet aggregation [3]. 
Along with aspirin, it is used to prevent ischemic episodes in coronary 
artery disease patients and to check the restenosis of stented 
coronaries and is found to have synergistic activity [4]. It is usually 
associated with various side effects ranging from diarrhea, epigastric 
pain, bleeding, neutropenia, thrombocytopenia, to bone marrow 
toxicity. Hypersensitivity reactions range from rashes, urticarial, to 
even life-threatening angioedema. Cutaneous adverse effects include 
mucocutaneous exanthemas, lichenoid eruptions, acute generalized 
exanthematous pustulosis, and fixed drug eruptions [3]. There are 
only a few cases of leukocytoclastic vasculitis due to clopidogrel been 
reported so far, and to the best of our knowledge, this is the second case 
to be reported [3]. The diagnostic criteria for leukocytoclastic vasculitis 
include age >16 years, proven temporal association of drug palpable 
purpura, maculopapular rash, biopsy of the skin showing neutrophils 
around an arteriole or venule [3]. In our case, the reaction started after 2 
months of clopidogrel therapy and patient developed palpable purpura. 
Patient was 65 years old and biopsy of the lesion revealed neutrophil 
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and eosinophil accumulation  around the arteriole. Our case was similar 
to the first case reported and the reaction occurred after starting 
clopidogrel therapy and subsided after the dose was reduced compared 
to one observed in the literature where the offending agent was stopped. 
Other etiological factors were ruled out. Causality assessment was done 
as per the Naranjo’s et al. scale [5], and a probable causal relationship 
was ascribed. The adverse reaction was found to be of mild severity and 
not preventable as per the Hartwig’s et al. severity [6] and Schumock 
and Thornton’s preventability scale [7], respectively.
CONCLUSION
Clopidogrel, essential drug used in prevention and treatment of 
coronary vascular disease, is used for long periods of time, so proper 
monitoring of adverse drug reactions is warranted. Furthermore, 
further studies can be done to find out the incidence of leukocytoclastic 
vasculitis associated with clopidogrel.
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Fig. 1: Maculopapular rash/palpable purpura after clopidogrel
